NCT04950218 (PSOCADIA) is a clinical trial in Psoriasis, sponsored by Herlev and Gentofte Hospital.

Who is sponsoring NCT04950218?

NCT04950218 is sponsored by Herlev and Gentofte Hospital.

What condition does NCT04950218 study?

NCT04950218 studies Psoriasis, Cardiovascular Diseases, Cardiovascular Risk Factor, Cardiovascular Pathology, Psoriasis Vulgaris, Psoriatic Nail, Psoriasis Face, Psoriasis Guttate, Psoriasis Gyrata, Psoriasis Diffusa, Psoriasis Palmaris, Psoriasis Annularis, Psoriasis Circinata, Psoriasis Plantaris, Psoriasis Universalis, Psoriasis Geographica, Left Ventricular Dysfunction, Myocardial Infarction, Myocardial Ischemia, Heart Failure, Stroke, Heart Diseases, Heart Failure, Systolic, Heart Failure, Diastolic.

Is NCT04950218 still recruiting?

NCT04950218 is currently recruiting now. Last updated 15 September 2025.

Last reviewed 2025-09-15 · How we verify

NCT04950218: PSOCADIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis

Recruiting now Last updated 15 September 2025

What this trial tests

trial in Psoriasis in 1,000 participants. Currently enrolling.

Timeline

1 September 2021

Primary endpoint
1 October 2034

1 October 2034

Quick facts

Lead sponsor	Herlev and Gentofte Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	1 September 2021
Primary completion	1 October 2034
Estimated completion	1 October 2034
Sites	1 location across Denmark

Conditions studied

Psoriasis — all drugs for Psoriasis →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Cardiovascular Risk Factor — all drugs for Cardiovascular Risk Factor →
Cardiovascular Pathology — all drugs for Cardiovascular Pathology →

Sponsor

Herlev and Gentofte Hospital

Who can join

18 and older, any sex, with Psoriasis or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In a prospective cohort study (n = 1.000), the investigators aim to investigate the correlation between cardiac biomarkers and advanced echocardiography and determine whether these are prognostic markers of heart disease in patients suffering from psoriasis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

High-sensitivity C-reactive protein is associated with altered cardiac structure and function in psoriasis: The PSOCADIA study.
Dons M, Sengeløv M, Skaarup KG, Johansen ND, et al · · 2025 · cited 1× · PMID 41280408 · DOI 10.1016/j.ijcha.2025.101832

Verify or expand the search:

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Herlev and Gentofte Hospital trials

Trials by the same sponsor.

NCT07493590 — CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction · not yet recruiting
NCT07321964 — The Effect of a Digital MediYoga Program on Quality of Life, Blood Pressure and Heart Rate Among Patients With Atrial Fi · NA · recruiting
NCT06706661 — Implementation of Nutritional Efforts on Discharged Older Patients · NA · recruiting
NCT06618417 — Evaluating the Impact of Home-Based Sleep Apnea Diagnostic on Well-Being, Health Behavior, and AF Load in Patients with · NA · recruiting
NCT06642272 — A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Hea · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04950218 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Herlev and Gentofte Hospital
Last refreshed: 15 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04950218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing